3SBio Inc. - Product Pipeline Review - 2016

Published: May, 2016 | Pages: 81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

3SBio Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, '3SBio Inc. - Product Pipeline Review - 2016', provides an overview of the 3SBio Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by 3SBio Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of 3SBio Inc.
- The report provides overview of 3SBio Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses 3SBio Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features 3SBio Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate 3SBio Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for 3SBio Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 3SBio Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
3SBio Inc. Snapshot 7
3SBio Inc. Overview 7
Key Information 7
Key Facts 7
3SBio Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
3SBio Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
3SBio Inc. - Pipeline Products Glance 16
3SBio Inc. - Late Stage Pipeline Products 16
Phase III Products/Combination Treatment Modalities 16
3SBio Inc. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
3SBio Inc. - Early Stage Pipeline Products 19
IND/CTA Filed Products/Combination Treatment Modalities 19
Preclinical Products/Combination Treatment Modalities 20
3SBio Inc. - Drug Profiles 21
(clindamycin phosphate + tretinoin) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
AT-101 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
SSS-06 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SSS-07 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
(tipiracil hydrochloride + trifluridine) 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
cinacalcet hydrochloride 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
colestilan chloride 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
eltrombopag olamine 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
nadroparin calcium 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PEG-EPO 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PEG-irinotecan 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
pegadricase 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
sevelamer carbonate 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
trelagliptin succinate 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(betamethasone valerate + calcipotriene) 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
APG-1387 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
desonide 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DJ-5 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DNP-001 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ferric citrate 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
fondaparinux sodium 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PMC-001 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecule to Inhibit HIF-PH for Renal Anemia 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SSS-08 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
thrombopoietin 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TTAC-0001 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
3SBio Inc. - Pipeline Analysis 55
3SBio Inc. - Pipeline Products by Target 55
3SBio Inc. - Pipeline Products by Route of Administration 57
3SBio Inc. - Pipeline Products by Molecule Type 58
3SBio Inc. - Pipeline Products by Mechanism of Action 59
3SBio Inc. - Recent Pipeline Updates 61
3SBio Inc. - Dormant Projects 75
3SBio Inc. - Discontinued Pipeline Products 76
Discontinued Pipeline Product Profiles 76
NuLeusin 76
3SBio Inc. - Company Statement 77
3SBio Inc. - Locations And Subsidiaries 78
Head Office 78
Other Locations & Subsidiaries 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables

3SBio Inc., Key Information 7
3SBio Inc., Key Facts 7
3SBio Inc. - Pipeline by Indication, 2016 9
3SBio Inc. - Pipeline by Stage of Development, 2016 11
3SBio Inc. - Monotherapy Products in Pipeline, 2016 12
3SBio Inc. - Combination Treatment Modalities in Pipeline, 2016 13
3SBio Inc. - Partnered Products in Pipeline, 2016 14
3SBio Inc. - Partnered Products/ Combination Treatment Modalities, 2016 15
3SBio Inc. - Phase III, 2016 16
3SBio Inc. - Phase II, 2016 17
3SBio Inc. - Phase I, 2016 18
3SBio Inc. - IND/CTA Filed, 2016 19
3SBio Inc. - Preclinical, 2016 20
3SBio Inc. - Pipeline by Target, 2016 55
3SBio Inc. - Pipeline by Route of Administration, 2016 57
3SBio Inc. - Pipeline by Molecule Type, 2016 58
3SBio Inc. - Pipeline Products by Mechanism of Action, 2016 60
3SBio Inc. - Recent Pipeline Updates, 2016 61
3SBio Inc. - Dormant Developmental Projects,2016 75
3SBio Inc. - Discontinued Pipeline Products, 2016 76
3SBio Inc., Other Locations 78
3SBio Inc., Subsidiaries 79